Daiichi drug shows non-inferiority to standard antithrombotic regimen in atrial fibrillation patients, adding to evidence supporting Factor Xa inhibitor's use.
Original Article: ENTRUST Bolsters Edoxaban As VKA Alternative In AF Patients